Elgemtumab Biosimilar Monoclonal Antibody (HER3) for Research

Cat No.: GMP-Bios-ab-170

Pre-Made Elgemtumab biosimilar, Whole mAb, Anti-ERBB3/Erbb-3 Antibody: Anti-ErbB-3/FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB-3/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Elgemtumab, also known as LJM716, is a high- affinity IgG1κ type monoclonal antibodies selected from a Human Combinatorial Antibody Library (HuCAL). It can specifically bind to ERBB3 to neutralize multiple modes of ERBB3 activation.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-170-1mg 1mg 3090

Size: 1mg | 10mg | 100mg



Product Details

Products Name (INN Index) Pre-Made Elgemtumab biosimilar, Whole mAb, Anti-ERBB3/Erbb-3 Antibody: Anti-ErbB-3/FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB-3/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3 therapeutic antibody
INN Name Elgemtumab
TargetErbb-3
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI Structure4p59:HL
Year Proposed2014
Year Recommended2015
CompaniesMorphoSys;Novartis;Memorial Sloan-Kettering Cancer Center;Novartis Oncology
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedBreast cancer;Gastric cancer;Head and neck cancer;Oesophageal cancer;Solid tumours
Development TechMedarex HuMAb Mouse



About target - ERBB3

1. Protein Receptor tyrosine-protein kinase erbB-3

2. Gene ERBB3

3. Organism Homo sapiens (Human)

Function
Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins. Binds to neuregulin-1 (NRG1) and is activated by it; ligand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase (PubMed:20682778).
May also be activated by CSPG5 (PubMed:15358134).
Involved in the regulation of myeloid cell differentiation (PubMed:27416908).

Catalytic activity
ATP + L-tyrosyl-[protein] = ADP + H+ + O-phospho-L-tyrosyl-[protein]
EC:2.7.10.1
Source: Rhea.